The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Twice-daily vs once-daily low-dose aspirin for ET: Results from the ARES trial
|
The phase II ARES trial (EudraCT 2016–002885-30) assessed the long-term pharmacodynamic superiority and safety of a twice-daily 100 mg aspirin regimen vs the standard once-daily regimen in 242 adult patients with essential thrombocythemia (ET).1 Results from this trial were published in the American Journal of Hematology by Rocca et al.1
|
| Key learnings1 |
| The primary endpoint was met; during a 20-month follow-up, patients who were treated with the twice-daily low-dose aspirin regimen showed significantly lower levels of serum thromboxane B2 compared with once-daily dosing (median, 3.9 vs 19.2 ng/ml; p < 0.001), suggesting enhanced antithrombotic efficacy. |
| Twice-daily low-dose aspirin dosing was associated with a reduction in disease-specific symptoms vs standard once-daily dosing (no reported symptoms, 17.3% vs 14.3%; p < 0.05; ≥8 reported symptoms; 7.9% vs 13.0%; p = 0.0001) and significant relief from severe hand and foot microvascular pain, without an increase in upper gastrointestinal discomfort. |
| Bleeding risks were similar between the twice-daily and once-daily aspirin regimens, although there was a trend towards more clinically relevant non-major bleeding in the twice-daily group (8 vs 2). |
| This study supports consideration of twice-daily low-dose aspirin as a well-tolerated and potentially more effective option for managing patients with ET, particularly in those with high symptom burden and risk of thrombotic events. |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content